Skip to content
A9662Assembly2023-2024 SessionSame asS8367

Cap COVID Drug Copays

Official title

“Relates to capping cost sharing for antiviral COVID-19 therapeutics”

Sponsor David WeprinAD-24Affects Finance
Status
In Assembly Committee
Insurance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires insurance and Medicaid plans in New York to cover FDA-approved COVID-19 antiviral drugs without deductibles or coinsurance.

Why it matters

  1. Reduces cost barriers for COVID-19 treatment. by ensuring that people with insurance or Medicaid in New York will not pay deductibles or coinsurance for FDA-approved COVID-19 antivirals, making timely treatment more accessible, especially for lower-income and vulnerable populations.

  2. Promotes public health and equity. by removing financial disincentives to seek early treatment for COVID-19, potentially reducing severe outcomes, hospitalizations, and community transmission rates.

  3. Integrates private, public, and government programs. by requiring patients to use free or reduced-cost programs from drug manufacturers or the government before tapping into insurance coverage, helping to manage overall healthcare spending and prevent unnecessary insurance claims.

  4. Sets a precedent for insurance coverage of pandemic-related therapeutics. , which could influence how other states or future public health emergencies are handled in terms of access and affordability of necessary treatments.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Cap COVID Drug Copays

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
David Weprin

Assembly Member · Assembly District 24

Chair, Insurance

No co-sponsors yet.

History

  1. Print number 9662a
  2. Amend and recommit to insurance
  3. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S8367Senate

Cap COVID Drug Costs

In Assembly Committee · Insurance · Sponsor Brad Hoylman-Sigal

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

9662--A

IN ASSEMBLY

March 27, 2024

Introduced by M. of A. WEPRIN -- read once and referred to the Committee on Insurance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the insurance law and the social services law, in relation to capping cost sharing for antiviral COVID-19 therapeutics

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 39 to read as follows:

(39) (A) Every policy that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(B) Coverage under this paragraph shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.

§ 2. Subsection (k) of section 3221 of the insurance law is amended by adding a new paragraph 23 to read as follows:

(23) (A) Every group or blanket policy delivered or issued for delivery in this state that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(B) Coverage under this paragraph shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD14144-05-4

§ 3. Section 4303 of the insurance law is amended by adding a new subsection (vv) to read as follows:

(vv) (1) Every contract issued by a medical expense indemnity corporation, a hospital service corporation, or a health service corporation that provides coverage for prescription drugs shall provide coverage for antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(2) Coverage under this subsection shall not be subject to annual deductibles or coinsurance, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this subsection.

§ 4. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (nn) to read as follows:

(nn) (i) antiviral therapeutics approved or granted emergency use authorization by the food and drug administration for the treatment of COVID-19 when prescribed by a licensed health care provider legally authorized to prescribe under title eight of the education law.

(ii) coverage under this paragraph shall be provided at no cost to the insured, provided, however, that an insured who is eligible for and able to obtain prescribed antiviral therapeutics at no cost or reduced cost under a manufacturer or government program may be required to use such program before using coverage required pursuant to this paragraph.

§ 5. This act shall take effect on the first day of January next succeeding the date on which it shall have become a law and shall apply to all policies and contracts issued, renewed, modified, altered, or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.